4 recruiting, 3 completed, 2 unknown, 1 active not recruiting. 8 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 4, Completed 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Delcath Systems Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases | Phase 1 / Phase 2 | Recruiting | University of Wisconsin, Madison | 15 | 2026-11-01 | 2026-10-30 |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine), Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) - Metastatic Breast Cancer in the Liver | Phase 2 | Recruiting | Delcath Systems Inc. | 90 | 2026-01-29 | 2026-10-19 |
| Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma Melphalan/HDS (Percutaneous Hepatic Perfusion), Tebentafusp - Metastatic Uveal Melanoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2025-12-31 | 2026-03-31 |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone - Refractory Metastatic Colorectal Cancer | Phase 2 | Recruiting | Delcath Systems Inc. | 90 | 2025-08-05 | 2026-10-20 |
| An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS) - Metastatic Ocular Melanoma, Metastatic Uveal Melanoma | Phase 3 | Active not recruiting | Delcath Systems Inc. | 30 | 2022-06-10 | 2023-12-21 |
| Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Melphalan/HDS, Cisplatin and Gemcitabine - Bile Duct Cancer, Intrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Unknown | Delcath Systems Inc. | 295 | 2018-04-10 | 2022-03-24 |
| Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma Melphalan/HDS - Ocular Melanoma, Uveal Melanoma | Phase 3 | Completed | Delcath Systems Inc. | 102 | 2016-02-01 | 2026-09-10 |
| Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy Hepatic Malignant Neoplasm Primary Non-Resectable | Unknown | Delcath Systems Inc. | 200 | 2016-01-14 | 2018-09-11 | |
| Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC Melphalan/HDS, Sorafenib - Hepatocellular Carcinoma (HCC) | Phase 2 | Withdrawn | Delcath Systems Inc. | 2014-10-01 | 2017-12-18 | |
| Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma Delcath Hepatic Delivery System, Melphalan - Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Terminated | Delcath Systems Inc. | 17 | 2014-06-01 | 2022-10-17 |
| Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma melphalan, regional chemotherapy, systemic chemotherapy - Intraocular Melanoma, Melanoma (Skin) | Phase 3 | Completed | Delcath Systems Inc. | 93 | 2006-02-01 | 2021-06-21 |
| Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer isolated perfusion, melphalan - Cancer | Phase 2 | Completed | Delcath Systems Inc. | 56 | 2004-09-01 | 2013-10-23 |
| Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver Melphalan, Percutaneous Hepatic Perfusion - Metastatic Liver Cancer, Ocular Melanoma | No longer available | Delcath Systems Inc. | 2013-10-23 |
Uveal Melanoma (6) · Melanoma (4) · Carcinoma, Hepatocellular (3) · Bile Duct Neoplasms (2) · Cholangiocarcinoma (2) · Rectal Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Appendiceal Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Islet Cell (1) · Carcinoma, Medullary (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Gallbladder Neoplasms (1)
Melphalan (7) · Bevacizumab (1) · Capecitabine (1) · Chemotherapy, Cancer, Regional Perfusion (1) · Cisplatin (1) · Gemcitabine (1) · Neoadjuvant Therapy (1) · Nivolumab (1) · Opdualag (1) · Sorafenib (1) · Vinorelbine (1) · eribulin (1) · relatlimab (1) · tebentafusp (1) · trifluridine tipiracil drug combination (1)
United States (11) · United Kingdom (4) · Germany (3) · Italy (3) · Spain (2) · Austria (1) · Belgium (1) · Czechia (1) · France (1) · Netherlands (1) · Serbia (1) · Sweden (1) · Switzerland (1) · Turkey (Türkiye) (1)
Jonathan Zager, MD (2) · Charles W Nutting, DO (1) · Eric D Whitman, MD (1) · H. Richard Alexander, MD (1) · James F Pingpank, MD (1) · Johnny John, MD (1) · Jonathan Zager, MD, FACS (1) · Leslie Callahan, RN (1) · Mark Faries, MD (1) · Marwan Fakih, MD (1) · Marybeth Hughes, MD (1) · Marybeth S. Hughes, MD (1) · Vincent Ma, MD (1)